Treatment of cancer with dual targeting of CD47 and EGFR

US12037402B2 · kind B2 · utility

Assignee

• The Board of Trustees of the Leland Stanford Junior University · US

Inventors

• Irving L. Weissman · Palo Alto, US
• Stephen Willingham · Stanford, US
• Doris Po Yi Ho · Daly City, US
• Piero D. Dalerba · New York, US
• Kelly Marie McKenna · Palo Alto, US
• Jens-Peter Volkmer · Menlo Park, US

Key dates

• Filing date: Aug 25, 2021
• Grant date: Jul 16, 2024
• Expiry date: Apr 22, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q1/6883
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods are provided for targeting cells for depletion, including, without limitation, cancer cells, in a regimen comprising contacting the targeted cells with a combination of agents, including (i) an agent that blockades CD47 activity; and (ii) an antibody that specifically binds to EGFR. In some embodiments the cancer cells have a mutated form of one or more of KRAS, NRAS and BRAF. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used.